Daniel Skiest to HIV Protease Inhibitors
This is a "connection" page, showing publications Daniel Skiest has written about HIV Protease Inhibitors.
Connection Strength
0.649
-
Skiest DJ, Cohen C, Mounzer K, Haigney Z, Barker D, Gottlieb M, Bellman PC, Dejesus E, Khanlou H, Ruane PJ, Hsiao CB, Abriola K, Rashbaum B, Bellos N, Ward D, Colson A, Santiago F, Habel A, Garb J. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients. HIV Clin Trials. 2011 May-Jun; 12(3):131-40.
Score: 0.343
-
Keiser P, Kvanli MB, Turner D, Reisch J, Smith JW, Nassar N, Gregg C, Skiest D. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 01; 20(1):28-33.
Score: 0.146
-
Iarikov DE, Irizarry-Acosta M, Martorell C, Hoffman RP, Skiest DJ. Low prevalence of primary HIV resistance in western Massachusetts. J Int Assoc Physicians AIDS Care (Chic). 2010 Jul-Aug; 9(4):227-31.
Score: 0.081
-
Scribner AN, Troia-Cancio PV, Cox BA, Marcantonio D, Hamid F, Keiser P, Levi M, Allen B, Murphy K, Jones RE, Skiest DJ. Osteonecrosis in HIV: a case-control study. J Acquir Immune Defic Syndr. 2000 Sep 01; 25(1):19-25.
Score: 0.041
-
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999 Dec 16; 341(25):1865-73.
Score: 0.039